Type I interferons in anticancer immunity

Laurence Zitvogel¹, Lorenzo Galluzzi², Oliver Kepp³, Mark J Smyth⁴, Guido Kroemer⁵

Affiliations

¹ 1] [2] INSERM, U1015, F-94800 Villejuif, France. [3] Université Paris Sud/Paris XI, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. [4] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif, France. [5].
² 1] [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [3] INSERM, U1138, F-75006 Paris, France. [4] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [5] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [6].
³ 1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France.
⁴ 1] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston QLD 4006, Australia. [2] School of Medicine, University of Queensland, Herston QLD 4006, Australia.
⁵ 1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France. [6] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, F-75015 Paris, France.

PMID: 26027717
DOI: 10.1038/nri3845

Review

Type I interferons in anticancer immunity

Laurence Zitvogel et al. Nat Rev Immunol. 2015 Jul.

. 2015 Jul;15(7):405-14.

doi: 10.1038/nri3845. Epub 2015 Jun 1.

Authors

Laurence Zitvogel¹, Lorenzo Galluzzi², Oliver Kepp³, Mark J Smyth⁴, Guido Kroemer⁵

Affiliations

¹ 1] [2] INSERM, U1015, F-94800 Villejuif, France. [3] Université Paris Sud/Paris XI, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. [4] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif, France. [5].
² 1] [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [3] INSERM, U1138, F-75006 Paris, France. [4] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [5] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [6].
³ 1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France.
⁴ 1] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston QLD 4006, Australia. [2] School of Medicine, University of Queensland, Herston QLD 4006, Australia.
⁵ 1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France. [6] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, F-75015 Paris, France.

PMID: 26027717
DOI: 10.1038/nri3845

Abstract

Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.

PubMed Disclaimer

References

1. Oncoimmunology. 2013 May 1;2(5):e24170 - PubMed
1. Nature. 2007 Dec 6;450(7171):903-7 - PubMed
1. J Clin Oncol. 2006 Jul 1;24(19):3164-71 - PubMed
1. Cancer Discov. 2014 Jun;4(6):674-87 - PubMed
1. Blood. 2011 Oct 13;118(15):4179-87 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Type I interferons in anticancer immunity

Affiliations

Type I interferons in anticancer immunity

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources